Table 1 Baseline characteristics ACPA-negative RA study population
A | ACPA-negative RA (n = 131) | Non-SDFR group (n = 68) | SDFR group (n = 63) |
Age (years), mean (SD) | 61 (15) | 57 (16) | 65 (11) |
Females, n (%) | 66 | 66 | 65 |
RF positivity, n (%) | 34 | 47 | 19 |
Symptom duration at diagnosis (≤ 12 weeks), n (%) | 45 | 41 | 50 |
DAS at baseline, med (IQR) | 3.5 (2.7–4.4) | 3.4 (2.7–4.2) | 3.6 (2.7–4.6) |
SJC at baseline (0–44), med (IQR) | 8 (3–12) | 8 (3–11) | 8 (3–13) |
TJC at baseline (0–53), med (IQR) | 9 (4–19) | 10 (4–19) | 9 (4–17) |
ESR (mm/h), med (IQR) | 28 (11–39) | 21 (13–37) | 29 (11–43) |
VAS (0–100 mm), med (IQR) | 50 (30–70) | 50 (30–60) | 60 (30–80) |
HAQ, med (IQR) | 1.1 (0.6–1.5) | 1.1 (0.6–1.5) | 1.1 (0.6–1.6) |
B | ACPA-negative replication population (n = 95) | Non-SDFR group (n = 50) | SDFR group (n = 45) |
Age (years), mean (SD) | 61 (17) | 60 (17) | 63 (17) |
Females, n (%) | 62 | 66 | 58 |
RF positivity, n (%) | 12* | 14 | 10 |
Symptom duration at diagnosis (≤ 12 weeks), n (%) | 44 | 53 | 34 |
DAS at baseline, med (IQR) | 3.6 (3.0–4.2) | 3.6 (3.0–4.2) | 3.7 (3.1–4.4) |
SJC at baseline, (0–44), med (IQR) | 8 (3–11) | 6 (3–10) | 8 (4–14) |
TJC at baseline, (0–53), med (IQR) | 13 (8–18) | 12 (7–18) | 13 (10–18) |
ESR (mm/h), med (IQR) | 22 (9–46) | 19 (9–41) | 22 (11–49) |
VAS (0–100 mm), med (IQR) | 32 (14–54)* | 29 (10–52) | 35 (16–18) |
HAQ, med (IQR) | 1.0 (0.6–1.8) | 1.1 (0.8–1.8) | 0.9 (0.6–1.6) |